RADNOR, PA / ACCESSWIRE / March 22, 2017 / Kessler Topaz Meltzer & Check, LLP reminds Vista Outdoor Inc. (NYSE: VSTO) (“Vista” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of Vista securities between August 11, 2016 and January 13, 2017, inclusive (the “Class Period”).

FINAL REMINDER: Shareholders who purchased Vista securities
during the Class Period may, no later than March 27, 2017, petition the Court to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/vista-outdoor-inc#join

Vista shareholders who wish to discuss their legal rights or interests with respect to this action are encouraged to contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or (610) 667 – 7706, or via e-mail at info@ktmc.com

Vista designs, manufactures and markets consumer products in the outdoor sports and recreation markets. Vista operates in two segments, Shooting Sports and Outdoor Products.

As detailed in the complaint, on January 11, 2017, Vista issued a press release entitled “Vista Outdoor Announces Expected Non-Cash Intangible Asset Impairment Charge.” Therein, Vista disclosed that it expected to record a material asset impairment charge in its Hunting and Shooting Accessories reporting unit in the third quarter of its fiscal year 2017 (“FY17”). Further, although Vista reported that it was still “in the process of finalizing the actual amount of the impairment, the Company’s preliminary analysis indicates the impairment charge will be in the range of $400 million to $450 million.” On this news, shares of the Company’s stock fell $8.21 per share, or 21.7%, to close on January 12, 2017 at $29.58 per share.

Then, on January 13, 2017, Vista disclosed that it had appointed a new President of its Outdoor Products segment. On this news, shares of the Company’s stock declined an additional $0.88 per share, or 3%, to close on January 13, 2017 at $28.70 per share.

The complaint alleges that, throughout the Class Period, the defendants failed to disclose: (1) that Vista was experiencing an acceleration in the softening of the retail environment and an acceleration in its own promotional activity; (2) that, as such, Vista was experiencing both revenue and gross margin declines; (3) that, as a result of the foregoing, the Company would have to begin the impairment assessment for its Outdoor Products segment’s reporting units in the third quarter of 2017, rather than with the preparation of the company’s FY17 annual financial statements; and (4) that, as a result, the Company would have to recognize an impairment charge in the range of $400 million to $450 million. The complaint further alleges that, as a result of the foregoing, the defendants’ statements about Vista’s business, operations and prospects were false and misleading and/or lacked a reasonable basis.

Vista shareholders may, no
later than March 27, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/vista-outdoor-inc#join

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Darren J. Check, Esq.

D. Seamus Kaskela, Esq.

Adrienne O. Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 453728

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ReWalk Robotics Ltd (“Rewalk” or the “Company”) (NASDAQ: RWLK). Investors, who purchased or otherwise acquired Rewalk shares pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014, are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, the Registration Statement and Prospectus issued regarding the Initial Public Offering did not disclose material information, including that ReWalk did not comply with “special controls” requirements.

When this information was revealed to the investing public, the value of Rewalk fell, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457941

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Roadrunner Transportation Systems Inc. (“Roadrunner” or the “Company”) (NYSE: RRTS). Investors, who purchased or otherwise acquired Roadrunner shares between May 8, 2014 and January 30, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 03, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Roadrunner disclosed on January 30, 2017 that its financial statements would need to be edited. The Company attributes the problem to accounting mistakes that Roadrunner anticipates will necessitate changes of $20 million to $25 million. When this information was released to the public, the value of Roadrunner dropped, causing shareholders serious harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 457938

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ: BABY). Investors, who purchased or otherwise acquired Natus shares between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 31, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Natus released materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects, including that: the government of Venezuela was unable to spend tens of millions of dollars in prepayments to Natus, needed in October 2015; that Natus did not have the capacity to effectively enforce its rights under its supply contract; Natus’ revenues related to the supply contract were dependent on the results of Venezuelan elections; and as therefore, Natus could not actually achieve the increased guidance offered by Defendants, which lacked a reasonable basis.

When this information was revealed to the public, the value of Natus Medical Incorporated stock declined, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457939

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BT Group plc (“BT Group” or the “Company”) (NYSE: BT) concerning possible violations of federal securities laws between May 10, 2013 and January 23, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 27, 2017 lead plaintiff motion deadline.

If you purchased shares of BT Group during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On January 24, 2017, BT Group announced a profit warning and noted that it was lowering its guidance for 2017 and 2018, due to an investigation into the accounting practices at its Italian company. When this information was released to the public, the value of BT Group stock dropped, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457935

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against PixarBio Corporation (“PixarBio” or the “Company”) (OTC PINK: PXRB). Investors, who purchased or otherwise acquired PixarBio shares between October 31, 2016, and January 20, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of PixarBio Corporation during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On January 23, 2017, the SEC disclosed the indefinite suspension of trading in the securities of PixarBio “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the Company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the Company’s current and prospective development efforts.” When this information was announced to the public, the value of PixarBio fell, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457936

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ: RGLS). Investors, who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Regulus revealed that it was contacted by the U.S. Food and Drug Administration (“FDA”), stating that its new drug against the chronic hepatitis C virus infection will be placed on clinical hold due to another incidence of jaundice.

On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency confirms the last safety and efficacy information from continued clinical and pre-clinical studies.

When this information was revealed to the investing public, shares of Regulus fell sharply, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457937

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Vista Outdoor, Inc. (“Vista” or the “Company”) (NYSE: VSTO) concerning possible violations of federal securities laws between August 11, 2016 and January 13, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Vista revealed that it is expecting a material asset impairment charge (approximately $400 – $450 million) to its Hunting and Shooting Accessories reporting unit during the third quarter of the 2017 fiscal year. When this news was revealed to investors, the value of Vista fell over 21% that day. Then, on January 13, 2017, Vista revealed that the President of its Outdoor Products segment, in which the Hunting and Shooting Accessories unit belongs, had resigned from his position. Following the release of this information to the investing public, the value of Vista declined, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457933

NEW YORK, NY / ACCESSWIRE / March 22, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the U.S. Physical Therapy, Inc. (“U.S. Physical Therapy” or the “Company”) (NYSE: USPH). Such investors are advised to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/usph.

The investigation concerns whether U.S. Physical Therapy and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On March 16, 2017, U.S. Physical Therapy revealed that it had discovered an accounting error. The Company stated that “it was determined that the Company’s historical accounting for redeemable non-controlling interests of acquired partnerships was incorrect due to the fact that those partnership agreements contain a provision that makes the non-controlling interests mandatorily redeemable and, thus incorrectly classified.” U.S. Physical Therapy also said that “[m]anagement has concluded that this error will result in the reporting of a material weakness in internal controls over financial reporting as they relate to this issue and that, as a result, ineffective internal controls over financial reporting. The error will require the restatement of previously issued financial statements.” Following this news, U.S. Physical Therapy stock has dropped as much as $7.75 per share, or 10.51%, during intraday trading on March 16, 2017.

If you are aware of any facts relating to this investigation, or purchased U.S. Physical Therapy shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/usph. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457862